Trial Profile
A prospective, observational study investigating safety and efficacy of ombitasvir/paritaprevir/ritonavir ± dasabuvir with or without ribavirin in chronic Hepatitis C patients with genotype 1 and 4 infection: a real life study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jul 2019
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 08 Jul 2017 New trial record